Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo Retraction in /10.3892/or.2020.7483

Li,Yang; Ma,Chengyuan; Qian,Ming; Wen,Zhongmei; Jing,Hongyu; Qian,Donghua

doi:10.3892/or.2014.2991

Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo

Retraction in: /10.3892/or.2020.7483

Authors:
- Yang Li
- Chengyuan Ma
- Ming Qian
- Zhongmei Wen
- Hongyu Jing
- Donghua Qian
View Affiliations

Affiliations: Department of Respiration, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Prosthodontics Department of the Stomatological Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/or.2014.2991
Pages: 1271-1276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is a lethal disease due to the absence of effective diagnostic biomarkers and therapeutic targets. Therefore, novel molecular targets are critically needed to formulate new approaches for this devastating disease. In the present study, using quantitive real-time PCR and immunohistochemistry. we initially found that expression of the ribosome assembly factor NIN/RPN12 binding protein (NOB1) was elevated in the majority of NSCLC tissues when compared to that in the normal lung tissue counterparts, and its expression level was correlated with key pathological characteristics including tumor differentiation, stage and metastasis. Then, the recombinant lentiviral shRNA expression vector carrying NOB1 was constructed and infected into the human NSCLC A549 cell line. Cell proliferation, cell apoptosis, cell cycle distribution and colony formation ability in A549 cells were assessed following downregulation of NOB1 by siRNA. In addition, tumor growth ability in nude mice was evaluated to define the function of NOB1 in cell transformation and tumorigenesis. It was found that downregulation of NOB1 expression using the RNA silencing approach in A549 tumor cells significantly suppressed the proliferation and colony formation ability, and induced tumor apoptosis in vitro. Tumor growth was also suppressed in vivo. These data suggest that NOB1 is an important regulator of the tumorigenic properties of human NSCLC and may be used as a new promising diagnostic biomarker and a potential anticancer therapeutic target for NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
3	Schiller JH: Small cell lung cancer: defining a role for emerging platinum drugs. Oncology. 63:105–114. 2002. View Article : Google Scholar : PubMed/NCBI
4	Stinchcombe TE and Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol. 4:243–250. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ramalingam S and Belani CP: Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets. 11:245–257. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Ni J, Zhou G, et al: Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep. 32:185–189. 2005. View Article : Google Scholar : PubMed/NCBI
7	Makarova KS, Aravind L, Galperin MY, et al: Comparative genomics of the Archaea (Euryarchaeota): evolution of conserved protein families, the stable core, and the variable shell. Genome Res. 9:608–628. 1999.PubMed/NCBI
8	Arcus VL, Backbro K, Roos A, Daniel EL and Baker EN: Distant structural homology leads to the functional characterization of an archaeal PIN domain as an exonuclease. J Biol Chem. 279:16471–16478. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lamanna AC and Karbstein K: Nob1 binds the single-stranded cleavage site D at the 3′-end of 18S rRNA with its PIN domain. Proc Natl Acad Sci USA. 106:14259–14264. 2009.PubMed/NCBI
10	Fatica A, Tollervey D and Dlakic M: PIN domain of Nob1p is required for D-site cleavage in 20S pre-rRNA. RNA. 10:1698–1701. 2004. View Article : Google Scholar : PubMed/NCBI
11	Fatica A, Oeffinger M, Dlakic M and Tollervey D: Nob1p is required for cleavage of the 3′ end of 18S rRNA. Mol Cell Biol. 23:1798–1807. 2003.
12	Huang WY, Chen DH, Ning L and Wang LW: siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells. Asian Pac J Cancer Prev. 13:1823–1827. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lu Z, Guo Q, Shi A, Xie F and Lu Q: Downregulation of NIN/RPN12 binding protein inhibits the growth of human hepatocellular carcinoma cells. Mol Biol Rep. 39:501–507. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lin Y, Peng S, Yu H, Teng H and Cui M: RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012.
15	Wu DP and He XW: Expression of NOB1 and its significance in colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao. 32:420–422. 2012.(in Chinese).
16	Lin S, Meng W, Zhang W, et al: Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma. J Int Med Res. 41:568–572. 2013.
17	Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE and Radich JP: The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 114:3292–3298. 2009. View Article : Google Scholar : PubMed/NCBI
18	Granneman S, Nandineni MR and Baserga SJ: The putative NTPase Fap7 mediates cytoplasmic 20S pre-rRNA processing through a direct interaction with Rps14. Mol Cell Biol. 25:10352–10364. 2005. View Article : Google Scholar : PubMed/NCBI
19	Ramos PC, Hockendorff J, Johnson ES, Varshavsky A and Dohmen RJ: Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly. Cell. 92:489–499. 1998. View Article : Google Scholar : PubMed/NCBI
20	Raychaudhuri S, Fontanes V, Barat B and Dasgupta A: Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res. 69:2057–2064. 2009. View Article : Google Scholar : PubMed/NCBI
21	Meraner J, Lechner M, Loidl A, et al: Acetylation of UBF changes during the cell cycle and regulates the interaction of UBF with RNA polymerase I. Nucleic Acids Res. 34:1798–1806. 2006. View Article : Google Scholar : PubMed/NCBI
22	Shirane M, Harumiya Y, Ishida N, et al: Down-regulation of p27^Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem. 274:13886–13893. 1999.PubMed/NCBI
23	Xu G, Bernaudo S, Fu G, Lee DY, Yang BB and Peng C: Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell. 19:4968–4979. 2008. View Article : Google Scholar : PubMed/NCBI
24	Fasanaro P, Capogrossi MC and Martelli F: Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. Cardiovasc Res. 85:272–280. 2010. View Article : Google Scholar : PubMed/NCBI
25	Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21^Cip1/Waf1 at both the G₁/S and the G₂/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 18:629–643. 1998.
26	Gu Y, Turck CW and Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 366:707–710. 1993.PubMed/NCBI
27	Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993. View Article : Google Scholar : PubMed/NCBI
28	Cai K and Dynlacht BD: Activity and nature of p21^WAF1 complexes during the cell cycle. Proc Natl Acad Sci USA. 95:12254–12259. 1998. View Article : Google Scholar : PubMed/NCBI
29	Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 17:4877–4882. 1997.PubMed/NCBI